>アジア太平洋地域の肺移植治療薬市場、製品別(免疫抑制剤、臓器保存製品、組織製品、その他)、適応症別(慢性閉塞性肺疾患(COPD)、肺線維症、敗血症性肺疾患、肺高血圧症、嚢胞性線維症、間質性肺線維症、肺気腫、サルコイドーシス、原発性肺動脈性高血圧症、その他)、タイプ別(死体肺移植、生体肺移植)、技術別(片肺移植、両肺移植、心肺移植、両肺移植)、患者層別(高齢者、成人、小児)、エンドユーザー別(病院、移植センター、専門センター、その他)、国別(日本、中国、韓国、インド、オーストラリア、シンガポール、タイ、マレーシア、ベトナム、インドネシア、フィリピン、その他アジア太平洋地域の産業動向と2029年までの予測
市場分析と洞察:アジア太平洋地域の肺移植治療市場
アジア太平洋地域の肺移植治療市場は、2022年から2029年の予測期間に市場成長が見込まれています。データブリッジマーケットリサーチは、市場は2022年から2029年の予測期間に3.2%のCAGRで成長し、2029年までに3,189万米ドルに達すると分析しています。主要な市場プレーヤーによる新製品の発売は、予測期間中の市場の需要を促進すると予想されます。
肺移植は、病気の肺を切除し、別の人の健康な肺と交換する手術です。肺移植手術は、新生児から成人まで、65 歳まで、場合によってはそれ以降のほぼすべての年齢の人に行うことができます。肺移植は、他の薬や治療を試したが、基礎疾患が十分に改善しなかった、または時間の経過とともに悪化した人のためのものです。患者の病状に応じて、肺移植では片方の肺または両方の肺を交換する場合があります。状況によっては、ドナーの心臓とともに肺を移植することもあります。肺移植は、患者の健康と生活の質を大幅に改善することができます。
医薬品の承認数の増加、臨床試験の増加、慢性疾患の高発生率、治療への応用拡大に向けた進行中の研究が、市場の成長を牽引すると予想されます。ただし、臓器提供者の減少と肺移植手術のコストの高さが市場の成長を妨げる可能性があります。一方、医療費の増加、市場プレーヤーによる戦略的取り組み、肺移植の技術的進歩が市場成長の機会を生み出す可能性があります。厳格な規制枠組みと肺移植に関連する合併症は、市場の成長を妨げる可能性があります。
アジア太平洋の肺移植治療市場レポートでは、市場シェア、新開発、製品パイプライン分析、国内および現地の市場プレーヤーの影響の詳細を提供し、新たな収益源、市場規制の変更、製品承認、戦略的決定、製品発売、地理的拡大、市場における技術革新の観点からの機会を分析します。分析と市場シナリオを理解するには、アナリスト概要についてお問い合わせください。当社のチームが、収益への影響ソリューションを作成し、希望する目標を達成できるようお手伝いします。
アジア太平洋地域の肺移植治療市場の範囲と市場規模
アジア太平洋地域の肺移植治療市場は、製品、タイプ、適応症、技術、患者の人口統計、およびエンドユーザーに分類されています。セグメント間の成長は、ニッチな成長分野と市場へのアプローチ戦略を分析し、コアアプリケーション領域とターゲット市場の違いを決定するのに役立ちます。
- 製品に基づいて、アジア太平洋地域の肺移植治療市場は、免疫抑制剤、組織製品、臓器保存製品、その他に分類されます。 2022年には、肺拒絶反応を回避するための免疫抑制剤の使用により、免疫抑制剤セグメントがアジア太平洋地域の肺移植治療市場を支配すると予想されます。
- タイプ別に見ると、アジア太平洋地域の肺移植治療市場は、死体肺移植と生体肺移植に分類されます。2022年には、臓器提供と登録に関する意識の高まりにより、死体肺移植セグメントがアジア太平洋地域の肺移植治療市場を支配すると予想されます。
- 適応症に基づいて、アジア太平洋地域の肺移植治療市場は、慢性閉塞性肺疾患(COPD)、肺線維症、敗血症性肺疾患、肺高血圧症、嚢胞性線維症、間質性肺線維症、肺気腫、原発性肺動脈性高血圧症サルコイドーシス、その他に分類されます。 2022年には、嚢胞性線維症患者の患者プールの急増により、嚢胞性線維症セグメントがアジア太平洋地域の肺移植治療市場を支配すると予想されます。
- アジア太平洋地域の肺移植治療市場は、技術に基づいて、片肺移植、両肺移植、心肺移植、両肺移植に分類されます。2022年には、肺移植手術の急増により、片肺移植(SLT)セグメントがアジア太平洋地域の肺移植治療市場を支配すると予想されます。
- 患者の人口統計に基づいて、アジア太平洋地域の肺移植治療市場は、成人、小児、老年に分類されます。2022年には、成人人口にみられる健康合併症の急増と、肺移植の手順を決定する移植を待つ成人患者の待機リストの増加により、成人セグメントがアジア太平洋地域の肺移植治療市場を支配すると予想されます。
- エンドユーザーに基づいて、アジア太平洋地域の肺移植治療市場は、病院、移植センター、専門センター、その他に分類されます。2022年には、臓器提供、登録、慢性疾患に関する意識の高まりにより、病院セグメントがアジア太平洋地域の肺移植治療市場を支配すると予想されます。
アジア太平洋地域の肺移植治療市場の国別分析
アジア太平洋地域の肺移植治療市場が分析され、製品、タイプ、適応症、技術、患者の人口統計、およびエンドユーザーに基づいて市場規模の情報が提供されます。
アジア太平洋地域の肺移植治療市場に含まれる国としては、日本、中国、韓国、インド、オーストラリア、シンガポール、タイ、マレーシア、ベトナム、インドネシア、フィリピン、その他のアジア太平洋地域が挙げられます。
アジア太平洋地域の免疫抑制剤セグメントは、慢性疾患を予防するための臨床試験と研究開発の増加により、2022年から2029年の予測期間に最高の成長率で成長すると予想されています。中国は、移植用医薬品の承認が増加し、研究開発への投資が継続的に増加し、医薬品の革新を促進しているため、アジア太平洋市場の成長をリードすると予想されています。インドは、高齢者人口の増加により、市場を支配すると予想されています。
レポートの国別セクションでは、市場の現在および将来の傾向に影響を与える個別の市場影響要因と市場規制の変更も提供しています。新規販売、交換販売、国の人口統計、規制行為、輸出入関税などのデータ ポイントは、個々の国の市場シナリオを予測するために使用される主要な指標の一部です。また、アジア太平洋ブランドの存在と可用性、および地元および国内ブランドとの競争が激しいか少ないために直面する課題、販売チャネルの影響を考慮しながら、国別データの予測分析を提供します。
医療費と慢性疾患の増加がアジア太平洋地域の肺移植治療市場の成長を促進
アジア太平洋の肺移植治療市場では、肺移植産業における各国の売上成長、肺移植技術の進歩の影響、肺移植治療市場への支援に関する規制シナリオの変化など、詳細な市場分析も提供しています。データは、2011年から2020年までの履歴期間で利用可能です。
競争環境とアジア太平洋地域の肺移植治療薬市場シェア分析
アジア太平洋の肺移植治療市場の競争状況は、競合他社の詳細を提供します。含まれる詳細には、会社概要、会社の財務状況、収益、市場の可能性、研究開発への投資、新しい市場への取り組み、生産拠点と施設、会社の強みと弱み、製品の発売、製品試験パイプライン、製品の承認、特許、製品の幅と広さ、アプリケーションの優位性、技術ライフライン曲線などがあります。上記のデータポイントは、アジア太平洋の肺移植治療市場への会社の重点にのみ関連しています。
アジア太平洋地域の肺移植治療薬市場の主要メーカーとしては、Apotex Inc、Bridge to Life Ltd、Intas Pharmaceuticals Ltd.、Viatris Inc.、Pfizer Inc.、F.Hoffmann-La Roche Ltd.、Panacea Biotec Ltd.、Astellas Pharma Inc.、Accord-UK Ltd、Novartis AG、Hikma Pharmaceuticals PLC、Detraxi Inc、Dr. Reddy's Laboratories Ltd.などが挙げられます。
さまざまな市場プレーヤーが、急速に成長しているヘルスケア分野と臓器移植における主要な技術開発を提供しています。
例えば、
- 2021年4月、アステラス製薬は日本証券アナリスト協会より「2021年ディスクロージャー優良企業賞」を受賞しました。これにより、同社は市場での地位を強化し、より多くの顧客基盤を獲得することができました。
コラボレーション、製品の発売、事業拡大、受賞や表彰、合弁事業、その他の市場プレーヤーとの提携により、アジア太平洋の肺移植治療市場における同社の地位が強化され、組織にとっても提供内容の改善に役立っています。
SKU-
世界初のマーケットインテリジェンスクラウドに関するレポートにオンラインでアクセスする
- インタラクティブなデータ分析ダッシュボード
- 成長の可能性が高い機会のための企業分析ダッシュボード
- カスタマイズとクエリのためのリサーチアナリストアクセス
- インタラクティブなダッシュボードによる競合分析
- 最新ニュース、更新情報、トレンド分析
- 包括的な競合追跡のためのベンチマーク分析のパワーを活用
目次
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF ASIA-PACIFIC LUNG TRANSPLANT THERAPEUTICS MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATIONS
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 DBMR TRIPOD DATA VALIDATION MODEL
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.6 MULTIVARIATE MODELLING
2.7 MARKET END USERS COVERAGE GRID
2.8 PRODUCT LIFELINE CURVE
2.9 DBMR MARKET POSITION GRID
2.1 VENDOR SHARE ANALYSIS
2.11 SECONDARY SOURCES
2.12 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 EPIDEMIOLOGY
4.2 PESTEL ANALYSIS
4.3 PORTER’S FIVE FORCES MODEL
5 INSURANCE AND REIMBURSEMENT - ASIA-PACIFIC LUNG TRANSPLANT THERAPEUTICS MARKET
5.1 U.S.
5.2 EUROPE
5.3 CANADA
5.4 INDIA
6 ASIA-PACIFIC LUNG TRANSPLANT THERAPEUTICS MARKET: REGULATIONS
6.1 REGULATION IN THE U.S.
6.2 REGULATION IN EUROPE
6.3 REGULATION IN NEW ZEALAND
6.4 REGULATION IN AUSTRALIA
7 MARKET OVERVIEW
7.1 DRIVERS
7.1.1 INCREASE IN INCIDENCE OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
7.1.2 RISE IN AIR POLLUTION AND SURGE IN SMOKING
7.1.3 HIGH INCIDENCE OF CHRONIC DISEASES
7.1.4 RISE IN CLINICAL TRIALS
7.1.5 INCREASING DRUG APPROVALS
7.2 RESTRAINTS
7.2.1 LESS NUMBER OF DONORS FOR ORGAN DONATION
7.2.2 HIGH COST OF ORGAN TRANSPLANTATION
7.3 OPPORTUNITIES
7.3.1 RISING HEALTHCARE SPENDING
7.3.2 STRATEGIC INITIATIVES BY MARKET PLAYERS
7.3.3 TECHNOLOGICAL ADVANCEMENTS IN LUNG TRANSPLANTATION
7.4 CHALLENGES
7.4.1 STRINGENT REGULATORY FRAMEWORK
7.4.2 COMPLICATIONS ASSOCIATED WITH LUNG TRANSPLANTATION
8 IMPACT OF COVID-19 ON LUNG TRANSPLANT THERAPEUTICS MARKET
8.1 IMPACT ON PRICE
8.2 IMPACT ON DEMAND
8.3 IMPACT ON SUPPLY CHAIN
8.4 STRATEGIC INITIATIVES
8.5 CONCLUSION
9 ASIA-PACIFIC LUNG TRANSPLANT THERAPEUTICS MARKET, BY PRODUCT
9.1 OVERVIEW
9.2 IMMUNOSUPPRESSANT DRUGS
9.2.1 BY CLASS
9.2.1.1 CALCINEURIN INHIBITORS
9.2.1.1.1 TACROLIMUS
9.2.1.1.2 CYCLOSPORIN
9.2.1.2 ANTIMETABOLITE IMMUNOSUPPRESANTS
9.2.1.2.1 MYCOPHENOLATE MOFETIL
9.2.1.2.2 MYCOPHENOLATE SODIUM
9.2.1.2.3 AZATHIOPRINE
9.2.1.3 M-TOR INHIBITOR
9.2.1.3.1 SIROLIMUS
9.2.1.3.2 EVEROLIMUS
9.2.1.4 STEROIDS
9.2.1.4.1 METHYLPREDNISOLONE
9.2.1.4.2 PREDNISONE
9.2.1.5 MONOCLONAL ANTIBODY
9.2.1.5.1 BASILIXIMAB
9.2.1.5.2 MUROMONAB
9.2.1.6 OTHERS
9.2.2 BY DRUG TYPE
9.2.2.1 BRANDED
9.2.2.2 GENERIC
9.2.3 ROUTE OF ADMINISTRATION
9.2.3.1 ORAL ADMINISTRATION
9.2.3.2 PARENTERAL ADMINISTRATION
9.3 ORGAN PRESERVATION PRODUCTS
9.3.1 PERFADEX
9.3.2 HUMAN BIOSYSTEM (HBS) SOLUTION
9.3.3 LIFOR
9.3.4 CUSTODIOL HTK-(HISTIDINE-TRYPTOPHAN-KETOGLUTARATE) SOLUTION
9.3.5 RENOGRAF
9.3.6 OTHERS
9.4 TISSUE PRODUCT
9.5 OTHERS
10 ASIA-PACIFIC LUNG TRANSPLANT THERAPEUTICS MARKET, BY TECHNIQUE
10.1 OVERVIEW
10.2 SINGLE-LUNG TRANSPLANT (SLT)
10.3 DOUBLE LUNG TRANSPLANT
10.4 BILATERAL LUNG TRANSPLANT (BLT)
10.5 HEART-LUNG TRANSPLANT
11 ASIA-PACIFIC LUNG TRANSPLANT THERAPEUTICS MARKET, BY PATIENT DEMOGRAPHICS
11.1 OVERVIEW
11.2 ADULTS
11.3 GERIATRIC
11.4 PEDIATRIC
12 ASIA-PACIFIC LUNG TRANSPLANT THERAPEUTICS MARKET, BY TYPE
12.1 OVERVIEW
12.2 CADAVERIC LUNG TRANSPLANT
12.3 LIVING LUNG TRANSPLANT
13 ASIA-PACIFIC LUNG TRANSPLANT THERAPEUTICS MARKET, BY INDICATION
13.1 OVERVIEW
13.2 CYSTIC FIBROSIS
13.3 PULMONARY FIBROSIS
13.4 CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
13.5 INTERSTITIAL PULMONARY FIBROSIS
13.6 PULMONARY HYPERTENSION
13.7 PRIMARY PULMONARY ARTERIAL HYPERTENSION
13.8 EMPHYSEMA
13.9 SARCOIDOSIS
13.1 SEPTIC LUNG DISEASE
13.11 OTHERS
14 ASIA-PACIFIC LUNG TRANSPLANT THERAPEUTICS MARKET, BY END USER
14.1 OVERVIEW
14.2 HOSPITAL
14.3 TRANSPLANT CENTERS
14.4 SPECIALTY CENTERS
14.5 OTHERS
15 ASIA-PACIFIC LUNG TRANSPLANT THERAPEUTICS MARKET, BY REGION
15.1 ASIA-PACIFIC
15.1.1 CHINA
15.1.2 INDIA
15.1.3 SOUTH KOREA
15.1.4 JAPAN
15.1.5 AUSTRALIA
15.1.6 THAILAND
15.1.7 MALAYSIA
15.1.8 PHILIPPINES
15.1.9 SINGAPORE
16 ASIA-PACIFIC LUNG TRANSPLANT THERAPEUTICS MARKET: COMPANY LANDSCAPE
16.1 COMPANY SHARE ANALYSIS: ASIA-PACIFIC
17 SWOT ANALYSIS
18 COMPANY PROFILE
18.1 ASTELLAS PHARMA INC.
18.1.1 COMPANY SNAPSHOT
18.1.2 REVENUE ANALYSIS
18.1.3 COMPANY SHARE ANALYSIS
18.1.4 PRODUCT PORTFOLIO
18.1.5 RECENT DEVELOPMENT
18.2 TRANSMEDICS (A SUBSIDIARY OF TRANSMEDICS GROUP, INC)
18.2.1 COMPANY SNAPSHOT
18.2.2 REVENUE ANALYSIS
18.2.3 COMPANY SHARE ANALYSIS
18.2.4 PRODUCT PORTFOLIO
18.2.5 RECENT DEVELOPMENT
18.3 DR. REDDY’S LABORATORIES LTD.
18.3.1 COMPANY SNAPSHOT
18.3.2 REVENUE ANALYSIS
18.3.3 COMPANY SHARE ANALYSIS
18.3.4 PRODUCT PORTFOLIO
18.3.5 RECENT DEVELOPMENT
18.4 F.HOFFMANN-LA ROCHE LTD.
18.4.1 COMPANY SNAPSHOT
18.4.2 REVENUE ANALYSIS
18.4.3 COMPANY SHARE ANALYSIS
18.4.4 PRODUCT PORTFOLIO
18.4.5 RECENT DEVELOPMENT
18.5 HIKMA PHARMACEUTICALS PLC
18.5.1 COMPANY SNAPSHOT
18.5.2 REVENUE ANALYSIS
18.5.3 COMPANY SHARE ANALYSIS
18.5.4 PRODUCT PORTFOLIO
18.5.5 RECENT DEVELOPMENT
18.6 APOTEX INC
18.6.1 COMPANY SNAPSHOT
18.6.2 PRODUCT PORTFOLIO
18.6.3 RECENT DEVELOPMENT
18.7 XVIVO
18.7.1 COMPANY SNAPSHOT
18.7.2 REVENUE ANALYSIS
18.7.3 PRODUCT PORTFOLIO
18.7.4 RECENT DEVELOPMENT
18.8 ACCORD-UK LTD
18.8.1 COMPANY SNAPSHOT
18.8.2 PRODUCT PORTFOLIO
18.8.3 RECENT DEVELOPMENT
18.9 BIOLIFE SOLUTIONS
18.9.1 COMPANY SNAPSHOT
18.9.2 REVENUE ANALYSIS
18.9.3 PRODUCT PORTFOLIO
18.9.4 RECENT DEVELOPMENT
18.1 BRIDGE TO LIFE LTD
18.10.1 COMPANY SNAPSHOT
18.10.2 PRODUCT PORTFOLIO
18.10.3 RECENT DEVELOPMENT
18.11 DETRAXI, INC.
18.11.1 COMPANY SNAPSHOT
18.11.2 PRODUCT PORTFOLIO
18.11.3 RECENT DEVELOPMENT
18.12 DR.FRANZ KOHLER CHEMIE GBMH
18.12.1 COMPANY SNAPSHOT
18.12.2 PRODUCT PORTFOLIO
18.12.3 RECENT DEVELOPMENT
18.13 INTAS PHARMACEUTICALS LTD.
18.13.1 COMPANY SNAPSHOT
18.13.2 PRODUCT PORTFOLIO
18.13.3 RECENT DEVELOPMENT
18.14 NOVARTIS AG
18.14.1 COMPANY SNAPSHOT
18.14.2 REVENUE ANALYSIS
18.14.3 PRODUCT PORTFOLIO
18.14.4 RECENT DEVELOPMENT
18.15 OSE-IMMUNO
18.15.1 COMPANY SNAPSHOT
18.15.2 PRODUCT PORTFOLIO
18.15.3 RECENT DEVELOPMENT
18.16 PANACEA BIOTEC LTD.
18.16.1 COMPANY SNAPSHOT
18.16.2 REVENUE ANALYSIS
18.16.3 PRODUCT PORTFOLIO
18.16.4 RECENT DEVELOPMENT
18.17 PARAGONIX TECHNOLOGIES, INC
18.17.1 COMPANY SNAPSHOT
18.17.2 PRODUCT PORTFOLIO
18.17.3 RECENT DEVELOPMENTS
18.17.3.1 PRODUCT LAUNCH
18.17.3.2 PARTNERSHIP
18.18 PFIZER INC.
18.18.1 COMPANY SNAPSHOT
18.18.2 REVENUE ANALYSIS
18.18.3 PRODUCT PORTFOLIO
18.18.4 RECENT DEVELOPMENT
18.19 VIATRIS, INC
18.19.1 COMPANY SNAPSHOT
18.19.2 REVENUE ANALYSIS
18.19.3 PRODUCT PORTFOLIO
18.19.4 RECENT DEVELOPMENT
18.20ST CENTURY MEDICINE
18.20.1 COMPANY SNAPSHOT
18.20.2 PRODUCT PORTFOLIO
18.20.3 RECENT DEVELOPMENT
19 QUESTIONNAIRE
20 RELATED REPORTS
表のリスト
TABLE 1 ASIA-PACIFIC LUNG TRANSPLANT THERAPEUTICS MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 2 ASIA-PACIFIC IMMUNOSUPPRESSANT DRUGS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 3 ASIA-PACIFIC IMMUNOSUPPRESSANT DRUGS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)
TABLE 4 ASIA-PACIFIC CALCINEURIN INHIBITORS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)
TABLE 5 ASIA-PACIFIC ANTIMETABOLITE IMMUNOSUPPRESANTS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)
TABLE 6 ASIA-PACIFIC M-TOR INHIBITOR IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)
TABLE 7 ASIA-PACIFIC STEROIDS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)
TABLE 8 ASIA-PACIFIC MONOCLONAL ANTIBODY IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)
TABLE 9 ASIA-PACIFIC IMMUNOSUPPRESSANT DRUGS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 10 ASIA-PACIFIC IMMUNOSUPPRESSANT DRUGS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 11 ASIA-PACIFIC ORGAN PRESERVATION PRODUCTS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 12 ASIA-PACIFIC ORGAN PRESERVATION PRODUCTS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 13 ASIA-PACIFIC TISSUE PRODUCT IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 14 ASIA-PACIFIC OTHERS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 15 ASIA-PACIFIC LUNG TRANSPLANT THERAPEUTICS MARKET, BY TECHNIQUE, 2020-2029 (USD MILLION)
TABLE 16 ASIA-PACIFIC SINGLE-LUNG TRANSPLANT (SLT) IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 17 ASIA-PACIFIC DOUBLE LUNG TRANSPLANT IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 18 ASIA-PACIFIC BILATERAL LUNG TRANSPLANT (BLT) IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 19 ASIA-PACIFIC HEART-LUNG TRANSPLANT IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 20 ASIA-PACIFIC LUNG TRANSPLANT THERAPEUTICS MARKET, BY PATIENT DEMOGRAPHICS, 2020-2029 (USD MILLION)
TABLE 21 ASIA-PACIFIC ADULTS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 22 ASIA-PACIFIC GERIATRIC IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 23 ASIA-PACIFIC PEDIATRIC IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 24 ASIA-PACIFIC LUNG TRANSPLANT THERAPEUTICS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 25 ASIA-PACIFIC CADAVERIC LUNG TRANSPLANT IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 26 ASIA-PACIFIC LIVING LUNG TRANSPLANT IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 27 ASIA-PACIFIC LUNG TRANSPLANT THERAPEUTICS MARKET, BY INDICATION, 2020-2029 (USD MILLION)
TABLE 28 ASIA-PACIFIC CYSTIC FIBROSIS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 29 ASIA-PACIFIC PULMONARY FIBROSIS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 30 ASIA-PACIFIC CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 31 ASIA-PACIFIC INTERSTITIAL PULMONARY FIBROSIS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 32 ASIA-PACIFIC PULMONARY HYPERTENSION IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 33 ASIA-PACIFIC PRIMARY PULMONARY ARTERIAL HYPERTENSION IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 34 ASIA-PACIFIC EMPHYSEMA IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 35 ASIA-PACIFIC SARCOIDOSIS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 36 ASIA-PACIFIC SEPTIC LUNG DISEASE IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 37 ASIA-PACIFIC OTHERS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 38 ASIA-PACIFIC LUNG TRANSPLANT THERAPEUTICS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 39 ASIA-PACIFIC HOSPITAL IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 40 ASIA-PACIFIC TRANSPLANT CENTERS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 41 ASIA-PACIFIC SPECIALTY CENTERS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 42 ASIA-PACIFIC OTHERS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 43 ASIA-PACIFIC LUNG TRANSPLANT THERAPEUTICS MARKET, BY COUNTRY, 2020-2029 (USD MILLION)
TABLE 44 ASIA-PACIFIC LUNG TRANSPLANT THERAPEUTICS MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 45 ASIA-PACIFIC IMMUNOSUPPRESSANT DRUGS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)
TABLE 46 ASIA-PACIFIC CALCINEURIN INHIBITORS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)
TABLE 47 ASIA-PACIFIC ANTIMETABOLITE IMMUNOSUPPRESANTS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)
TABLE 48 ASIA-PACIFIC M-TOR INHIBITOR IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)
TABLE 49 ASIA-PACIFIC STEROIDS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)
TABLE 50 ASIA-PACIFIC MONOCLONAL ANTIBODY IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)
TABLE 51 ASIA-PACIFIC IMMUNOSUPRRESANT DRUGS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 52 ASIA-PACIFIC IMMUNOSUPPRESANT DRUGS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 53 ASIA-PACIFIC ORGAN PRESERVATION PRODUCTS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 54 ASIA-PACIFIC LUNG TRANSPLANT THERAPEUTICS MARKET, BY INDICATION, 2020-2029 (USD MILLION)
TABLE 55 ASIA-PACIFIC LUNG TRANSPLANT THERAPEUTICS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 56 ASIA-PACIFIC LUNG TRANSPLANT THERAPEUTICS MARKET, BY TECHNIQUE, 2020-2029 (USD MILLION)
TABLE 57 ASIA-PACIFIC LUNG TRANSPLANT THERAPEUTICS MARKET, BY PATIENT DEMOGRAPHICS, 2020-2029 (USD MILLION)
TABLE 58 ASIA-PACIFIC LUNG TRANSPLANT THERAPEUTICS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 59 CHINA LUNG TRANSPLANT THERAPEUTICS MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 60 CHINA IMMUNOSUPPRESSANT DRUGS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)
TABLE 61 CHINA CALCINEURIN INHIBITORS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)
TABLE 62 CHINA ANTIMETABOLITE IMMUNOSUPPRESANTS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)
TABLE 63 CHINA M-TOR INHIBITOR IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)
TABLE 64 CHINA STEROIDS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)
TABLE 65 CHINA MONOCLONAL ANTIBODY IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)
TABLE 66 CHINA IMMUNOSUPRRESANT DRUGS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 67 CHINA IMMUNOSUPPRESANT DRUGS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 68 CHINA ORGAN PRESERVATION PRODUCTS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 69 CHINA LUNG TRANSPLANT THERAPEUTICS MARKET, BY INDICATION, 2020-2029 (USD MILLION)
TABLE 70 CHINA LUNG TRANSPLANT THERAPEUTICS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 71 CHINA LUNG TRANSPLANT THERAPEUTICS MARKET, BY TECHNIQUE, 2020-2029 (USD MILLION)
TABLE 72 CHINA LUNG TRANSPLANT THERAPEUTICS MARKET, BY PATIENT DEMOGRAPHICS, 2020-2029 (USD MILLION)
TABLE 73 CHINA LUNG TRANSPLANT THERAPEUTICS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 74 INDIA LUNG TRANSPLANT THERAPEUTICS MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 75 INDIA IMMUNOSUPPRESSANT DRUGS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)
TABLE 76 INDIA CALCINEURIN INHIBITORS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)
TABLE 77 INDIA ANTIMETABOLITE IMMUNOSUPPRESANTS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)
TABLE 78 INDIA M-TOR INHIBITOR IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)
TABLE 79 INDIA STEROIDS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)
TABLE 80 INDIA MONOCLONAL ANTIBODY IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)
TABLE 81 INDIA IMMUNOSUPRRESANT DRUGS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 82 INDIA IMMUNOSUPPRESANT DRUGS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 83 INDIA ORGAN PRESERVATION PRODUCTS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 84 INDIA LUNG TRANSPLANT THERAPEUTICS MARKET, BY INDICATION, 2020-2029 (USD MILLION)
TABLE 85 INDIA LUNG TRANSPLANT THERAPEUTICS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 86 INDIA LUNG TRANSPLANT THERAPEUTICS MARKET, BY TECHNIQUE, 2020-2029 (USD MILLION)
TABLE 87 INDIA LUNG TRANSPLANT THERAPEUTICS MARKET, BY PATIENT DEMOGRAPHICS, 2020-2029 (USD MILLION)
TABLE 88 INDIA LUNG TRANSPLANT THERAPEUTICS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 89 SOUTH KOREA LUNG TRANSPLANT THERAPEUTICS MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 90 SOUTH KOREA IMMUNOSUPPRESSANT DRUGS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)
TABLE 91 SOUTH KOREA CALCINEURIN INHIBITORS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)
TABLE 92 SOUTH KOREA ANTIMETABOLITE IMMUNOSUPPRESANTS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)
TABLE 93 SOUTH KOREA M-TOR INHIBITOR IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)
TABLE 94 SOUTH KOREA STEROIDS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)
TABLE 95 SOUTH KOREA MONOCLONAL ANTIBODY IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)
TABLE 96 SOUTH KOREA IMMUNOSUPRRESANT DRUGS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 97 SOUTH KOREA IMMUNOSUPPRESANT DRUGS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 98 SOUTH KOREA ORGAN PRESERVATION PRODUCTS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 99 SOUTH KOREA LUNG TRANSPLANT THERAPEUTICS MARKET, BY INDICATION, 2020-2029 (USD MILLION)
TABLE 100 SOUTH KOREA LUNG TRANSPLANT THERAPEUTICS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 101 SOUTH KOREA LUNG TRANSPLANT THERAPEUTICS MARKET, BY TECHNIQUE, 2020-2029 (USD MILLION)
TABLE 102 SOUTH KOREA LUNG TRANSPLANT THERAPEUTICS MARKET, BY PATIENT DEMOGRAPHICS, 2020-2029 (USD MILLION)
TABLE 103 SOUTH KOREA LUNG TRANSPLANT THERAPEUTICS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 104 JAPAN LUNG TRANSPLANT THERAPEUTICS MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 105 JAPAN IMMUNOSUPPRESSANT DRUGS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)
TABLE 106 JAPAN CALCINEURIN INHIBITORS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)
TABLE 107 JAPAN ANTIMETABOLITE IMMUNOSUPPRESANTS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)
TABLE 108 JAPAN M-TOR INHIBITOR IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)
TABLE 109 JAPAN STEROIDS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)
TABLE 110 JAPAN MONOCLONAL ANTIBODY IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)
TABLE 111 JAPAN IMMUNOSUPRRESANT DRUGS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 112 JAPAN IMMUNOSUPPRESANT DRUGS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 113 JAPAN ORGAN PRESERVATION PRODUCTS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 114 JAPAN LUNG TRANSPLANT THERAPEUTICS MARKET, BY INDICATION, 2020-2029 (USD MILLION)
TABLE 115 JAPAN LUNG TRANSPLANT THERAPEUTICS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 116 JAPAN LUNG TRANSPLANT THERAPEUTICS MARKET, BY TECHNIQUE, 2020-2029 (USD MILLION)
TABLE 117 JAPAN LUNG TRANSPLANT THERAPEUTICS MARKET, BY PATIENT DEMOGRAPHICS, 2020-2029 (USD MILLION)
TABLE 118 JAPAN LUNG TRANSPLANT THERAPEUTICS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 119 AUSTRALIA LUNG TRANSPLANT THERAPEUTICS MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 120 AUSTRALIA IMMUNOSUPPRESSANT DRUGS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)
TABLE 121 AUSTRALIA CALCINEURIN INHIBITORS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)
TABLE 122 AUSTRALIA ANTIMETABOLITE IMMUNOSUPPRESANTS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)
TABLE 123 AUSTRALIA M-TOR INHIBITOR IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)
TABLE 124 AUSTRALIA STEROIDS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)
TABLE 125 AUSTRALIA MONOCLONAL ANTIBODY IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)
TABLE 126 AUSTRALIA IMMUNOSUPRRESANT DRUGS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 127 AUSTRALIA IMMUNOSUPPRESANT DRUGS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 128 AUSTRALIA ORGAN PRESERVATION PRODUCTS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 129 AUSTRALIA LUNG TRANSPLANT THERAPEUTICS MARKET, BY INDICATION, 2020-2029 (USD MILLION)
TABLE 130 AUSTRALIA LUNG TRANSPLANT THERAPEUTICS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 131 AUSTRALIA LUNG TRANSPLANT THERAPEUTICS MARKET, BY TECHNIQUE, 2020-2029 (USD MILLION)
TABLE 132 AUSTRALIA LUNG TRANSPLANT THERAPEUTICS MARKET, BY PATIENT DEMOGRAPHICS, 2020-2029 (USD MILLION)
TABLE 133 AUSTRALIA LUNG TRANSPLANT THERAPEUTICS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 134 THAILAND LUNG TRANSPLANT THERAPEUTICS MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 135 THAILAND IMMUNOSUPPRESSANT DRUGS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)
TABLE 136 THAILAND CALCINEURIN INHIBITORS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)
TABLE 137 THAILAND ANTIMETABOLITE IMMUNOSUPPRESANTS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)
TABLE 138 THAILAND M-TOR INHIBITOR IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)
TABLE 139 THAILAND STEROIDS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)
TABLE 140 THAILAND MONOCLONAL ANTIBODY IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)
TABLE 141 THAILAND IMMUNOSUPRRESANT DRUGS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 142 THAILAND IMMUNOSUPPRESANT DRUGS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 143 THAILAND ORGAN PRESERVATION PRODUCTS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 144 THAILAND LUNG TRANSPLANT THERAPEUTICS MARKET, BY INDICATION, 2020-2029 (USD MILLION)
TABLE 145 THAILAND LUNG TRANSPLANT THERAPEUTICS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 146 THAILAND LUNG TRANSPLANT THERAPEUTICS MARKET, BY TECHNIQUE, 2020-2029 (USD MILLION)
TABLE 147 THAILAND LUNG TRANSPLANT THERAPEUTICS MARKET, BY PATIENT DEMOGRAPHICS, 2020-2029 (USD MILLION)
TABLE 148 THAILAND LUNG TRANSPLANT THERAPEUTICS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 149 MALAYSIA LUNG TRANSPLANT THERAPEUTICS MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 150 MALAYSIA IMMUNOSUPPRESSANT DRUGS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)
TABLE 151 MALAYSIA CALCINEURIN INHIBITORS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)
TABLE 152 MALAYSIA ANTIMETABOLITE IMMUNOSUPPRESANTS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)
TABLE 153 MALAYSIA M-TOR INHIBITOR IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)
TABLE 154 MALAYSIA STEROIDS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)
TABLE 155 MALAYSIA MONOCLONAL ANTIBODY IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)
TABLE 156 MALAYSIA IMMUNOSUPRRESANT DRUGS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 157 MALAYSIA IMMUNOSUPPRESANT DRUGS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 158 MALAYSIA ORGAN PRESERVATION PRODUCTS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 159 MALAYSIA LUNG TRANSPLANT THERAPEUTICS MARKET, BY INDICATION, 2020-2029 (USD MILLION)
TABLE 160 MALAYSIA LUNG TRANSPLANT THERAPEUTICS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 161 MALAYSIA LUNG TRANSPLANT THERAPEUTICS MARKET, BY TECHNIQUE, 2020-2029 (USD MILLION)
TABLE 162 MALAYSIA LUNG TRANSPLANT THERAPEUTICS MARKET, BY PATIENT DEMOGRAPHICS, 2020-2029 (USD MILLION)
TABLE 163 MALAYSIA LUNG TRANSPLANT THERAPEUTICS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 164 PHILIPPINES LUNG TRANSPLANT THERAPEUTICS MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 165 PHILIPPINES IMMUNOSUPPRESSANT DRUGS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)
TABLE 166 PHILIPPINES CALCINEURIN INHIBITORS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)
TABLE 167 PHILIPPINES ANTIMETABOLITE IMMUNOSUPPRESANTS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)
TABLE 168 PHILIPPINES M-TOR INHIBITOR IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)
TABLE 169 PHILIPPINES STEROIDS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)
TABLE 170 PHILIPPINES MONOCLONAL ANTIBODY IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)
TABLE 171 PHILIPPINES IMMUNOSUPRRESANT DRUGS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 172 PHILIPPINES IMMUNOSUPPRESANT DRUGS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 173 PHILIPPINES ORGAN PRESERVATION PRODUCTS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 174 PHILIPPINES LUNG TRANSPLANT THERAPEUTICS MARKET, BY INDICATION, 2020-2029 (USD MILLION)
TABLE 175 PHILIPPINES LUNG TRANSPLANT THERAPEUTICS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 176 PHILIPPINES LUNG TRANSPLANT THERAPEUTICS MARKET, BY TECHNIQUE, 2020-2029 (USD MILLION)
TABLE 177 PHILIPPINES LUNG TRANSPLANT THERAPEUTICS MARKET, BY PATIENT DEMOGRAPHICS, 2020-2029 (USD MILLION)
TABLE 178 PHILIPPINES LUNG TRANSPLANT THERAPEUTICS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 179 SINGAPORE LUNG TRANSPLANT THERAPEUTICS MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 180 SINGAPORE IMMUNOSUPPRESSANT DRUGS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)
TABLE 181 SINGAPORE CALCINEURIN INHIBITORS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)
TABLE 182 SINGAPORE ANTIMETABOLITE IMMUNOSUPPRESANTS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)
TABLE 183 SINGAPORE M-TOR INHIBITOR IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)
TABLE 184 SINGAPORE STEROIDS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)
TABLE 185 SINGAPORE MONOCLONAL ANTIBODY IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)
TABLE 186 SINGAPORE IMMUNOSUPRRESANT DRUGS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 187 SINGAPORE IMMUNOSUPPRESANT DRUGS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 188 SINGAPORE ORGAN PRESERVATION PRODUCTS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 189 SINGAPORE LUNG TRANSPLANT THERAPEUTICS MARKET, BY INDICATION, 2020-2029 (USD MILLION)
TABLE 190 SINGAPORE LUNG TRANSPLANT THERAPEUTICS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 191 SINGAPORE LUNG TRANSPLANT THERAPEUTICS MARKET, BY TECHNIQUE, 2020-2029 (USD MILLION)
TABLE 192 SINGAPORE LUNG TRANSPLANT THERAPEUTICS MARKET, BY PATIENT DEMOGRAPHICS, 2020-2029 (USD MILLION)
TABLE 193 SINGAPORE LUNG TRANSPLANT THERAPEUTICS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 194 INDONESIA LUNG TRANSPLANT THERAPEUTICS MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 195 INDONESIA IMMUNOSUPPRESSANT DRUGS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)
TABLE 196 INDONESIA CALCINEURIN INHIBITORS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)
TABLE 197 INDONESIA ANTIMETABOLITE IMMUNOSUPPRESANTS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)
TABLE 198 INDONESIA M-TOR INHIBITOR IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)
TABLE 199 INDONESIA STEROIDS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)
TABLE 200 INDONESIA MONOCLONAL ANTIBODY IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)
TABLE 201 INDONESIA IMMUNOSUPRRESANT DRUGS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 202 INDONESIA IMMUNOSUPPRESANT DRUGS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 203 INDONESIA ORGAN PRESERVATION PRODUCTS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 204 INDONESIA LUNG TRANSPLANT THERAPEUTICS MARKET, BY INDICATION, 2020-2029 (USD MILLION)
TABLE 205 INDONESIA LUNG TRANSPLANT THERAPEUTICS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 206 INDONESIA LUNG TRANSPLANT THERAPEUTICS MARKET, BY TECHNIQUE, 2020-2029 (USD MILLION)
TABLE 207 INDONESIA LUNG TRANSPLANT THERAPEUTICS MARKET, BY PATIENT DEMOGRAPHICS, 2020-2029 (USD MILLION)
TABLE 208 INDONESIA LUNG TRANSPLANT THERAPEUTICS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 209 VIETNAM LUNG TRANSPLANT THERAPEUTICS MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 210 VIETNAM IMMUNOSUPPRESSANT DRUGS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)
TABLE 211 VIETNAM CALCINEURIN INHIBITORS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)
TABLE 212 VIETNAM ANTIMETABOLITE IMMUNOSUPPRESANTS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)
TABLE 213 VIETNAM M-TOR INHIBITOR IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)
TABLE 214 VIETNAM STEROIDS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)
TABLE 215 VIETNAM MONOCLONAL ANTIBODY IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)
TABLE 216 VIETNAM IMMUNOSUPRRESANT DRUGS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 217 VIETNAM IMMUNOSUPPRESANT DRUGS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 218 VIETNAM ORGAN PRESERVATION PRODUCTS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 219 VIETNAM LUNG TRANSPLANT THERAPEUTICS MARKET, BY INDICATION, 2020-2029 (USD MILLION)
TABLE 220 VIETNAM LUNG TRANSPLANT THERAPEUTICS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 221 VIETNAM LUNG TRANSPLANT THERAPEUTICS MARKET, BY TECHNIQUE, 2020-2029 (USD MILLION)
TABLE 222 VIETNAM LUNG TRANSPLANT THERAPEUTICS MARKET, BY PATIENT DEMOGRAPHICS, 2020-2029 (USD MILLION)
TABLE 223 VIETNAM LUNG TRANSPLANT THERAPEUTICS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 224 REST OF ASIA-PACIFIC LUNG TRANSPLANT THERAPEUTICS MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
図表一覧
FIGURE 1 ASIA-PACIFIC LUNG TRANSPLANT THERAPEUTICS MARKET: SEGMENTATION
FIGURE 2 ASIA-PACIFIC LUNG TRANSPLANT THERAPEUTICS MARKET: DATA TRIANGULATION
FIGURE 3 ASIA-PACIFIC LUNG TRANSPLANT THERAPEUTICS MARKET: DROC ANALYSIS
FIGURE 4 ASIA-PACIFIC LUNG TRANSPLANT THERAPEUTICS MARKET: ASIA-PACIFIC VS REGIONAL MARKET ANALYSIS
FIGURE 5 ASIA-PACIFIC LUNG TRANSPLANT THERAPEUTICS MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 ASIA-PACIFIC LUNG TRANSPLANT THERAPEUTICS MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 ASIA-PACIFIC LUNG TRANSPLANT THERAPEUTICS MARKET: MARKET END USERS COVERAGE GRID
FIGURE 8 ASIA-PACIFIC LUNG TRANSPLANT THERAPEUTICS MARKET: DBMR MARKET POSITION GRID
FIGURE 9 ASIA-PACIFIC LUNG TRANSPLANT THERAPEUTICS MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 ASIA-PACIFIC LUNG TRANSPLANT THERAPEUTICS MARKET: SEGMENTATION
FIGURE 11 TECHNOLOGICAL ADVANCEMENTS IN HEALTHCARE AND SURGICAL SEGMENTS ASSOCIATED WITH ORGAN TRANSPLANTATION IS EXPECTED TO DRIVE THE ASIA-PACIFIC LUNG TRANSPLANT THERAPEUTICS MARKET IN THE FORECAST PERIOD OF 2022 TO 2029
FIGURE 12 IMMUNOSUPPRESSANTS SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE ASIA-PACIFIC LUNG TRANSPLANT THERAPEUTICS MARKET IN 2022 & 2029
FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF ASIA-PACIFIC LUNG TRANSPLANT THERAPEUTICS MARKET
FIGURE 14 ASIA-PACIFIC LUNG TRANSPLANT THERAPEUTICS MARKET: BY PRODUCT, 2021
FIGURE 15 ASIA-PACIFIC LUNG TRANSPLANT THERAPEUTICS MARKET: BY PRODUCT, 2020-2029 (USD MILLION)
FIGURE 16 ASIA-PACIFIC LUNG TRANSPLANT THERAPEUTICS MARKET: BY PRODUCT, CAGR (2022-2029)
FIGURE 17 ASIA-PACIFIC LUNG TRANSPLANT THERAPEUTICS MARKET: BY PRODUCT, LIFELINE CURVE
FIGURE 18 ASIA-PACIFIC LUNG TRANSPLANT THERAPEUTICS MARKET: BY TECHNIQUE, 2021
FIGURE 19 ASIA-PACIFIC LUNG TRANSPLANT THERAPEUTICS MARKET: BY TECHNIQUE, 2020-2029 (USD MILLION)
FIGURE 20 ASIA-PACIFIC LUNG TRANSPLANT THERAPEUTICS MARKET: BY TECHNIQUE, CAGR (2022-2029)
FIGURE 21 ASIA-PACIFIC LUNG TRANSPLANT THERAPEUTICS MARKET: BY TECHNIQUE, LIFELINE CURVE
FIGURE 22 ASIA-PACIFIC LUNG TRANSPLANT THERAPEUTICS MARKET: BY PATIENT DEMOGRAPHICS, 2021
FIGURE 23 ASIA-PACIFIC LUNG TRANSPLANT THERAPEUTICS MARKET: BY PATIENT DEMOGRAPHICS, 2020-2029 (USD MILLION)
FIGURE 24 ASIA-PACIFIC LUNG TRANSPLANT THERAPEUTICS MARKET: BY PATIENT DEMOGRAPHICS, CAGR (2022-2029)
FIGURE 25 ASIA-PACIFIC LUNG TRANSPLANT THERAPEUTICS MARKET: BY PATIENT DEMOGRAPHICS, LIFELINE CURVE
FIGURE 26 ASIA-PACIFIC LUNG TRANSPLANT THERAPEUTICS MARKET: BY TYPE, 2021
FIGURE 27 ASIA-PACIFIC LUNG TRANSPLANT THERAPEUTICS MARKET: BY TYPE, 2022-2029 (USD MILLION)
FIGURE 28 ASIA-PACIFIC LUNG TRANSPLANT THERAPEUTICS MARKET: BY TYPE, CAGR (2022-2029)
FIGURE 29 ASIA-PACIFIC LUNG TRANSPLANT THERAPEUTICS MARKET: BY TYPE, LIFELINE CURVE
FIGURE 30 ASIA-PACIFIC LUNG TRANSPLANT THERAPEUTICS MARKET : BY INDICATION, 2021
FIGURE 31 ASIA-PACIFIC LUNG TRANSPLANT THERAPEUTICS MARKET : BY INDICATION, 2020-2029 (USD MILLION)
FIGURE 32 ASIA-PACIFIC LUNG TRANSPLANT THERAPEUTICS MARKET : BY INDICATION, CAGR (2022-2029)
FIGURE 33 ASIA-PACIFIC LUNG TRANSPLANT THERAPEUTICS MARKET : BY INDICATION, LIFELINE CURVE
FIGURE 34 ASIA-PACIFIC LUNG TRANSPLANT THERAPEUTICS MARKET : BY END USER, 2021
FIGURE 35 ASIA-PACIFIC LUNG TRANSPLANT THERAPEUTICS MARKET : BY END USER, 2020-2029 (USD MILLION)
FIGURE 36 ASIA-PACIFIC LUNG TRANSPLANT THERAPEUTICS MARKET : BY END USER, CAGR (2022-2029)
FIGURE 37 ASIA-PACIFIC LUNG TRANSPLANT THERAPEUTICS MARKET : BY END USER, LIFELINE CURVE
FIGURE 38 ASIA-PACIFIC LUNG TRANSPLANT THERAPEUTICS MARKET: SNAPSHOT (2021)
FIGURE 39 ASIA-PACIFIC LUNG TRANSPLANT THERAPEUTICS MARKET: BY COUNTRY (2021)
FIGURE 40 ASIA-PACIFIC LUNG TRANSPLANT THERAPEUTICS MARKET: BY COUNTRY (2022 & 2029)
FIGURE 41 ASIA-PACIFIC LUNG TRANSPLANT THERAPEUTICS MARKET: BY COUNTRY (2021 & 2029)
FIGURE 42 ASIA-PACIFIC LUNG TRANSPLANT THERAPEUTICS MARKET: BY PRODUCT (2022-2029)
FIGURE 43 ASIA-PACIFIC LUNG TRANSPLANT THERAPEUTICS MARKET: COMPANY SHARE 2021 (%)
調査方法
データ収集と基準年分析は、大規模なサンプル サイズのデータ収集モジュールを使用して行われます。この段階では、さまざまなソースと戦略を通じて市場情報または関連データを取得します。過去に取得したすべてのデータを事前に調査および計画することも含まれます。また、さまざまな情報ソース間で見られる情報の不一致の調査も含まれます。市場データは、市場統計モデルと一貫性モデルを使用して分析および推定されます。また、市場シェア分析と主要トレンド分析は、市場レポートの主要な成功要因です。詳細については、アナリストへの電話をリクエストするか、お問い合わせをドロップダウンしてください。
DBMR 調査チームが使用する主要な調査方法は、データ マイニング、データ変数が市場に与える影響の分析、および一次 (業界の専門家) 検証を含むデータ三角測量です。データ モデルには、ベンダー ポジショニング グリッド、市場タイムライン分析、市場概要とガイド、企業ポジショニング グリッド、特許分析、価格分析、企業市場シェア分析、測定基準、グローバルと地域、ベンダー シェア分析が含まれます。調査方法について詳しくは、お問い合わせフォームから当社の業界専門家にご相談ください。
カスタマイズ可能
Data Bridge Market Research は、高度な形成的調査のリーダーです。当社は、既存および新規のお客様に、お客様の目標に合致し、それに適したデータと分析を提供することに誇りを持っています。レポートは、対象ブランドの価格動向分析、追加国の市場理解 (国のリストをお問い合わせください)、臨床試験結果データ、文献レビュー、リファービッシュ市場および製品ベース分析を含めるようにカスタマイズできます。対象競合他社の市場分析は、技術ベースの分析から市場ポートフォリオ戦略まで分析できます。必要な競合他社のデータを、必要な形式とデータ スタイルでいくつでも追加できます。当社のアナリスト チームは、粗い生の Excel ファイル ピボット テーブル (ファクト ブック) でデータを提供したり、レポートで利用可能なデータ セットからプレゼンテーションを作成するお手伝いをしたりすることもできます。